SynthesisClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Effectiveness and Safety of Aspirin Versus Other Antithrombotics for VTE After Total Hip and Knee Arthroplasty in Real-World Setting.
Synthesis in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundVenous thromboembolism (VTE) is a potentially life-threatening complication in patients undergoing total hip arthroplasty (THA) and total knee arthroplasty (TKA). Multiple antithrombotic agents are routinely used to prevent VTE after THA and TKA. However, it remains unclear which anticoagulant is optimal in real-world clinical practice. This study aimed to assess the effectiveness and safety of aspirin and other antithrombotic agents for VTE prophylaxis following THA and TKA.MethodsSeveral electronic databases, including PubMed, Embase, and the Cochrane Library, were systematically searched from inception to January 13th, 2025. The search identified real-world studies assessing the efficacy or safety of aspirin versus other anticoagulants for VTE prophylaxis after THA or TKA. The pooled rate of thromboembolic and bleeding events was estimated using a random-effects model. Two reviewers independently screened the literature and extracted data. Subgroup analyses were conducted based on study type, dose regimen and geographic region.ResultsA total of 41 studies were identified for inclusion. The overall incidence of VTE after THA and TKA with low-molecular-weight heparin (LMWH) was 1.20% (95% CI: 0.90%-1.60%). The incidence of VTE for aspirin, warfarin and direct oral anticoagulants (DOACs) was 0.80%, 0.9% and 0.90%, respectively. The pooled incidence of major bleeding for aspirin (1.90%, 95% CI: 0.00%-4.60%) was statistically significantly different from that in patients receiving LMWH (3.50%, 95% CI: 0.00%-7.80%) and DOACs (3.10%, 95% CI: 1.20%- 5.00%). When analyzing regional subgroups among several antithrombotic agents, VTE rate was significantly higher in Asia (LMWH: 21.80%, aspirin: 2.40%, DOACs: 9.40%) compared to other regions. In terms of major bleeding, the higher rate associated with DOACs (5.00%, 95% CI: 0.90%-9.20%) was found in North America compared to other regions, especially among patients treated with rivaroxaban (4.10%, 95% CI: 1.20%-7.00%).ConclusionTo date, this study provides the most comprehensive real-world evidence regarding antithrombotic agents for VTE prophylaxis after THA and TKA. Aspirin appears to be as effective as other antithrombotic agents for VTE prophylaxis following THA and TKA. Furthermore, its use is associated with a significantly lower risk of bleeding. Nevertheless, these findings should be interpreted carefully.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.